RECOMBINANT EXPRESSION OF SMALL MOLECULE PATHWAYS

Information

  • Research Project
  • 2535881
  • ApplicationId
    2535881
  • Core Project Number
    R43CA076811
  • Full Project Number
    1R43CA076811-01
  • Serial Number
    76811
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1997 - 27 years ago
  • Project End Date
    9/29/1998 - 26 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1997 - 27 years ago
  • Budget End Date
    9/29/1998 - 26 years ago
  • Fiscal Year
    1997
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/29/1997 - 27 years ago
Organizations

RECOMBINANT EXPRESSION OF SMALL MOLECULE PATHWAYS

This Phase I project will develop a recombinant system to stably clone and express multigene pathways encoding bioactive compounds. Due to the proliferation of antibiotic resistant strains of microbial pathogens and to demographic shifts the need for novel antibiotics, anticancer agents and other compounds greatly exceeds the present discovery rate despite recent increases in the screening efforts and the development of combinatorial techniques. A vast repository of pathways encoding potentially useful bioactive compounds resides within the uncultivated fraction of naturally occurring microbes; however, approaches to date have not successfully accessed this resource. As a first stem towards this goal, in Phase l a shuttle vector system will be developed based on an F factor replicon for stable propagation of clones in E coli and containing genes/sites for replication or integration in Streptomyces to express pathways encoding known polyketide antibiotics. In Phase II, these vectors will be used to construct "environmental libraries" containing the collective genomes of uncultivated microbes captured in substrate-doped traps designed to attract actinomycetes and other microbes likely to produce novel bioactive compounds. PROPOSED COMMERCIAL APPLICATION: This work will lead to the discovery of novel bioactive compounds including antibiotics, anti-infectives, anti-cancer and anti-inflammatory agents.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG5
  • Study Section Name
  • Organization Name
    DIVERSA CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921213829
  • Organization District
    UNITED STATES